Molecular neurobiological clues to the pathogenesis of bipolar disorder

Current Opinion in Neurobiology

Volumn 36, Issue , 2016, Pages 1-6

  Harrison, Paul J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; ANK3 PROTEIN, HUMAN; ANKYRIN; CACNA1C PROTEIN, HUMAN; CALCIUM CHANNEL L TYPE;

ANK3 GENE; BIPOLAR DISORDER; CACNA1C GENE; CALCIUM SIGNALING; CELL ADHESION; CELL DIFFERENTIATION; CIRCADIAN RHYTHM; DOPAMINERGIC SYSTEM; GENE; GENE LOCUS; GENETIC ASSOCIATION; HERITABILITY; HUMAN; MOUSE MODEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; PHENOTYPE;

ANIMALS; ANKYRINS; BIPOLAR DISORDER; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CELL ADHESION; CELL DIFFERENTIATION; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHENOTYPE; TRANSCRIPTOME;

EID: 84937792734     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2015.07.002     Document Type: Review

References (49)

1. Phillips M.L., Kupfer D.J. Bipolar disorder diagnosis: challenges and future directions. Lancet 2013, 381:1663-1671.
2. Bourne C., Aydemir O., Balanza-Martinez V., Bora E., Brissos S., Cavanagh J.T., Clark L., Cubukcuoglu Z., Dias V.V., Dittmann S., et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013, 128:149-162.
3. Broome M., Saunders K.E.A., Harrison P.J., Marwaha S. Mood instability. Br J Psychiatry 2015, (in press).
4. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet 2013, 381:1672-1682.
5. Craddock N., Sklar P. Genetics of bipolar disorder. Lancet 2013, 381:1654-1662.
6. Andreazza A.C., Young L.T. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int J Neuropsychopharmacol 2014, 17:1039-1052.
7. Shinozaki G., Potash J.B. New developments in the genetics of bipolar disorder. Curr Psychiatry Rep 2014, 16:493.
8. Harrison P.J. Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol 2015, 29:85-96.
9. Winham S.J., Cuellar-Barboza A.B., Oliveros A., McElroy S.L., Crow S., Colby C., Choi D.S., Chauhan M., Frye M., Biernacka J.M. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry 2014, 19:1010-1016.
10. Neale B.M., Sklar P. Genetic analysis of schizophrenia and bipolar disorder reveals polygenicity but also suggests new directions for molecular interrogation. Curr Opin Neurobiol 2015, 30:131-138.
11. Cross-Disorder Group of the Psychiatric Genomics Consortium Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-1379.
12. Cardno A.G., Owen M.J. Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr Bull 2014, 40:504-515.
13. Albert F.W., Kruglyak L. The role of regulatory variation in complex traits and disease. Nat Rev Genet 2015, 16:197-212.
14. Gamazon E.R., Badner J.A., Cheng L., Zhang C., Zhang D., Cox N.J., Gershon E.S., Kelsoe J.R., Greenwood T.A., Nievergelt C.M., et al. Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry 2013, 18:340-346.
15. Roussos P., Mitchell A.C., Voloudakis G., Fullard J.F., Pothula V.M., Tsang J., Stahl E.A., Georgakopoulos A., Ruderfer D.M., Charney A., et al. A role for noncoding variation in schizophrenia. Cell Rep 2014, 9:1417-1429.
16. Gershon E.S., Grennan K., Busnello J., Badner J.A., Ovsiew F., Memon S., Alliey-Rodriguez N., Cooper J., Romanos B., Liu C. A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain. Mol Psychiatry 2014, 19:890-894.
17. Ament S.A., Szelinger S., Glusman G., Ashworth J., Hou L., Akula N., Shekhtman T., Badner J.A., Brunkow M.E., Mauldin D.E., et al. Rare variants in neuronal excitability genes influence risk for bipolar disorder. Proc Natl Acad Sci U S A 2015, 112:3576-3581.
18. Bhat S., Dao D.T., Terrillion C.E., Arad M., Smith R.J., Soldatov N.M., Gould T.D. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol 2012, 99:1-14.
19. Berridge M.J. Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia. Cell Tissue Res 2014, 357:477-492.
20. Nurnberger J.I., Koller D.L., Jung J., Edenberg H.J., Foroud T., Guella I., Vawter M.P., Kelsoe J.R., Psychiatric Genomics Consortium Bipolar G. Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry 2014, 71:657-664.
21. Network, Pathway Analysis Subgroup of Psychiatric Genomics Consortium Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 2015, 18:199-209.
22. Kleinman J.E., Law A.J., Lipska B.K., Hyde T.M., Ellis J.K., Harrison P.J., Weinberger D.R. Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains. Biol Psychiatry 2011, 69:140-145.
23. Bigos K.L., Mattay V.S., Callicott J.H., Straub R.E., Vakkalanka R., Kolachana B., Hyde T.M., Lipska B.K., Kleinman J.E., Weinberger D.R. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch Gen Psychiatry 2010, 67:939-945.
24. Bennett V., Healy J. Membrane domains based on ankyrin and spectrin associated with cell-cell interactions. Cold Spring Harb Perspect Biol 2009, 1:a003012.
25. Rasband M.N. The axon initial segment and the maintenance of neuronal polarity. Nat Rev Neurosci 2010, 11:552-562.
26. Ho T.S., Zollinger D.R., Chang K.J., Xu M., Cooper E.C., Stankewich M.C., Bennett V., Rasband M.N. A hierarchy of ankyrin-spectrin complexes clusters sodium channels at nodes of Ranvier. Nat Neurosci 2014, 17:1664-1672.
27. Chang K.J., Zollinger D.R., Susuki K., Sherman D.L., Makara M.A., Brophy P.J., Cooper E.C., Bennett V., Mohler P.J., Rasband M.N. Glial ankyrins facilitate paranodal axoglial junction assembly. Nat Neurosci 2014, 17:1673-1681.
28. Durak O., de Anda F.C., Singh K.K., Leussis M.P., Petryshen T.L., Sklar P., Tsai L.H. Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of beta-catenin. Mol Psychiatry 2015, 20:388-397.
29. Smith K.R., Kopeikina K.J., Fawcett-Patel J.M., Leaderbrand K., Gao R., Schurmann B., Myczek K., Radulovic J., Swanson G.T., Penzes P. Psychiatric risk factor ANK3/ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses. Neuron 2014, 84:399-415.
30. Nanavati D., Austin D.R., Catapano L.A., Luckenbaugh D.A., Dosemeci A., Manji H.K., Chen G., Markey S.P. The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome. J Neurochem 2011, 119:617-629.
31. Wirgenes K.V., Tesli M., Inderhaug E., Athanasiu L., Agartz I., Melle I., Hughes T., Andreassen O.A., Djurovic S. ANK3 gene expression in bipolar disorder and schizophrenia. Br J Psychiatry 2014, 205:244-245.
32. Roussos P., Katsel P., Davis K.L., Bitsios P., Giakoumaki S.G., Jogia J., Rozsnyai K., Collier D., Frangou S., Siever L.J., et al. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch Gen Psychiatry 2012, 69:7-15.
33. Rueckert E.H., Barker D., Ruderfer D., Bergen S.E., O'Dushlaine C., Luce C.J., Sheridan S.D., Theriault K.M., Chambert K., Moran J., et al. Cis-acting regulation of brain-specific ANK3 gene expression by a genetic variant associated with bipolar disorder. Mol Psychiatry 2013, 18:922-929.
34. Hess J.L., Quinn T.P., Akbarian S., Glatt S.J. Bioinformatic analyses and conceptual synthesis of evidence linking ZNF804A to risk for schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2015, 168B:14-35.
35. Hill M.J., Bray N.J. Evidence that schizophrenia risk variation in the ZNF804A gene exerts its effects during fetal brain development. Am J Psychiatry 2012, 169:1301-1308.
36. Tao R., Cousijn H., Jaffe A.E., Burnet P.W., Edwards F., Eastwood S.L., Shin J.H., Lane T.A., Walker M.A., Maher B.J., et al. Expression of ZNF804A in human brain and alterations in schizophrenia, bipolar disorder, and major depressive disorder: a novel transcript fetally regulated by the psychosis risk variant rs1344706. JAMA Psychiatry 2014, 71:1112-1120.
37. Han K., Holder J.L., Schaaf C.P., Lu H., Chen H., Kang H., Tang J., Wu Z., Hao S., Cheung S.W., et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013, 503:72-77.
38. McClung C.A. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007, 114:222-232.
39. Sidor M.M., Spencer S.M., Dzirasa K., Parekh P.K., Tye K.M., Warden M.R., Arey R.N., Enwright J.F., Jacobsen J.P., Kumar S., et al. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry 2015, 10.1038/mp.2014.167.
40. Chung S., Lee E.J., Yun S., Choe H.K., Park S.B., Son H.J., Kim K.S., Dluzen D.E., Lee I., Hwang O., et al. Impact of circadian nuclear receptor REV-ERBalpha on midbrain dopamine production and mood regulation. Cell 2014, 157:858-868.
41. Leussis M.P., Berry-Scott E.M., Saito M., Jhuang H., de Haan G., Alkan O., Luce C.J., Madison J.M., Sklar P., Serre T., et al. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol Psychiatry 2013, 73:683-690.
42. Chen H.M., DeLong C.J., Bame M., Rajapakse I., Herron T.J., McInnis M.G., O'Shea K.S. Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients. Transl Psychiatry 2014, 4:e375.
43. Wang J.L., Shamah S.M., Sun A.X., Waldman I.D., Haggarty S.J., Perlis R.H. Label-free, live optical imaging of reprogrammed bipolar disorder patient-derived cells reveals a functional correlate of lithium responsiveness. Transl Psychiatry 2014, 4:e428.
44. Madison J.M., Zhou F., Nigam A., Hussain A., Barker D.D., Nehme R., van der Ven K., Hsu J., Wolf P., Fleishman M., et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Mol Psychiatry 2015, 20:703-717.
45. Yoshimizu T., Pan J.Q., Mungenast A.E., Madison J.M., Su S., Ketterman J., Ongur D., McPhie D., Cohen B., Perlis R., et al. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol Psychiatry 2015, 20:162-169.
46. Chiu C.T., Wang Z., Hunsberger J.G., Chuang D.M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013, 65:105-142.
47. Farhy Tselnicker I., Tsemakhovich V., Rishal I., Kahanovitch U., Dessauer C.W., Dascal N. Dual regulation of G proteins and the G-protein-activated K+ channels by lithium. Proc Natl Acad Sci U S A 2014, 111:5018-5023.
48. Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 2015, 20:661-670.
49. Mühleisen T.W., Leber M., Schulze T.G., Strohmaier J., Degenhardt F., Treutlein J., Mattheisen M., Forstner A.J., Schumacher J., Breuer R., et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun 2014, 5:3339.